Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Replimune GroupREPL +1.97%27 Equity-to-Asset is 0.50 as of Mar. 2026, which is 36% below its 10-year median of 0.78. GuruFocus rates REPL with a GF Score™ of 27/100. The stock has 4 warning signs investors should review. Among 1,415 Biotechnology companies, Replimune Group ranks worse than 67.21% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Replimune Group's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $166.16 Mil. Replimune Group's Total Assets for the quarter that ended in Mar. 2026 was $332.39 Mil.
The historical rank and industry rank for Replimune Group's Equity-to-Asset or its related term are showing as below:
REPL'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.51 Med: 0.78 Max: 0.92
Current: 0.5
During the past 10 years, the highest Equity to Asset Ratio of Replimune Group was 0.92. The lowest was -0.51. And the median was 0.78.
REPL's Equity-to-Asset is ranked worse than 67.21% of 1415
companies
in the Biotechnology industry
Industry Median: 0.68
vs REPL: 0.50
Replimune Group (NAS:REPL) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Replimune Group Equity-to-Asset Related Terms
Replimune Group Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Replimune Group's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
REPL vs ANNX, SLDB, ABUS: Equity-to-Asset Comparison
For the Biotechnology subindustry, Replimune Group's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Replimune Group Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Replimune Group's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Replimune Group's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Replimune Group's Equity to Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Replimune Group (REPL) has a Equity-to-Asset of 0.50 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Replimune Group and its competitors. This is 36% below median its historical median of 0.78. According to the industry distribution chart, Replimune Group ranks #951 out of 1415 companies in the Biotechnology industry, placing it in the top 67.2%.
Is Replimune Group's Equity-to-Asset too high?
Replimune Group's current Equity-to-Asset of 0.50 is 36% below median its 10-year median of 0.78. The Biotechnology industry median Equity-to-Asset is 0.68. Replimune Group's value of 0.50 is 26.5% below this industry median. Based on the distribution chart, Replimune Group ranks #951 out of 1415 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Replimune Group has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Replimune Group's Equity-to-Asset compare to ANNX and SLDB?
According to the Biotechnology industry distribution chart, Replimune Group ranks #951 out of 1415 companies for Equity-to-Asset. This places Replimune Group in the lower half of its industry. The industry median Equity-to-Asset is 0.68. Replimune Group's value of 0.50 is 26.5% below this benchmark. While the company's 10-year median is 0.78 vs. the industry median of 0.68, Replimune Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,415 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Replimune Group's current Equity-to-Asset of 0.50 is 26.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Replimune Group and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Replimune Group's current Equity-to-Asset is 0.50, which is 36% below median its own 10-year median of 0.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Replimune Group stock overvalued right now?
Replimune Group (REPL) has a current Equity-to-Asset of 0.50. The current Equity-to-Asset is 0.50, which is 36% below median its 10-year median of 0.78 and 26.5% below the Biotechnology industry median of 0.68. Replimune Group's overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Replimune Group (REPL), the current Equity-to-Asset is 0.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
27GF Score
Get the complete analysis for REPL
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
REPL has been successfully added to your 
